Clinical Trial

Long Term Follow-up for RGX-202

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
RGX-202-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-202 in participants who have received RGX-202 (an investigative gene therapy designed to deliver a transgene for novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain) in a separate parent study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-01; most recent amendment 2026-03-23.
Trial Details
NCT Number NCT06491927
Lead Sponsor REGENXBIO Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 66 participants
Start Date 2024-05-08
Primary Completion 2029-12-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-24